Spider Phobia Opposite Action Treatment Study

Sponsor
University of Texas at Austin (Other)
Overall Status
Terminated
CT.gov ID
NCT02905279
Collaborator
(none)
44
1
4
18.4
2.4

Study Details

Study Description

Brief Summary

This study tests the effectiveness of exposure therapy for fear of spiders as enhanced by the use of antagonistic or opposite actions during treatment. The goal of the study is to compare the efficacy threat-relevant opposite actions and threat-irrelevant opposite actions in extinguishing fear.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Biofeedback Relaxation Training
  • Behavioral: Exposure Therapy
  • Behavioral: Exposure with Threat-Relevant Opposite Actions
  • Behavioral: Exposure with Threat-Irrelevant Opposite Actions
N/A

Detailed Description

This study tests whether exposure therapy for fear of spiders can be enhanced with the use of opposite actions, which are actions opposite to fear-related action tendencies. The investigators will test two sub-types of opposite actions (a) threat-relevant opposite actions, which are actions antagonistic to specific threats associated with spider phobia, and (b) threat-irrelevant opposite actions, which are actions antagonistic to the fear response, but unrelated to specific threats associated with spider phobia. This exposure therapy enhanced with opposite actions will be compared with two control groups: standard exposure therapy and non-specific anxiety treatment (biofeedback relaxation training).

Individuals between the ages of 18-65 with elevated fear of spiders are randomly assigned to one of four treatment conditions (1) biofeedback relaxation training, (2) standard exposure therapy, (3) exposure therapy with threat-relevant opposite actions, and (4) exposure therapy with threat-irrelevant opposite actions. All participants undergo an online prescreen and a face-to-face screening assessment to determine eligibility and baseline (pre-treatment) symptom severity. Participants additionally complete assessments directly after treatment (post-treatment), and approximately two weeks after treatment (follow-up). The pre-treatment assessment occurs on the same day as treatment, the post-treatment assessment occurs during the treatment visit as soon as the treatment procedure is complete, and the follow-up assessment occurs within a window of 14-21 days after the completion of treatment. Participants complete two behavioral approach tests (in the treatment context and in the generalization context) at pre-treatment, post-treatment, and follow-up. Participants complete a battery of self-report questionnaires at pre-treatment and follow-up.

Study Design

Study Type:
Interventional
Actual Enrollment :
44 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Enhancing Exposure Therapy for Spider Phobia With the Use of Threat-Relevant and Threat-Irrelevant Opposite Actions
Actual Study Start Date :
Jun 1, 2016
Actual Primary Completion Date :
Dec 3, 2017
Actual Study Completion Date :
Dec 12, 2017

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Biofeedback

Biofeedback Relaxation Training

Behavioral: Biofeedback Relaxation Training
Participants will receive one-session biofeedback relaxation training (24 minutes) for anxiety reduction. Prior to biofeedback, participants will receive education about spiders and the development and maintenance of spider phobia.

Active Comparator: Standard Exposure

Exposure Therapy

Behavioral: Exposure Therapy
Participants will receive one-session exposure therapy (24 minutes) for fear of spiders. Prior to exposure therapy, participants will receive education about spiders and the development and the development and maintenance of spider phobia.

Experimental: Exposure with Threat-Relevant OAs.

Exposure with Threat-Relevant Opposite Actions

Behavioral: Exposure with Threat-Relevant Opposite Actions
Participants will receive one-session exposure therapy (24 minutes) for fear of spiders. During exposure, participants will engage in actions opposite to the tendencies associated with threat avoidance. Prior to exposure therapy, participants will receive education about spiders and the development and maintenance of spider phobia.

Experimental: Exposure with Threat-Irrelevant OAs

Exposure with Threat-Irrelevant Opposite Actions

Behavioral: Exposure with Threat-Irrelevant Opposite Actions
Participants will receive one-session exposure therapy (24 minutes) for fear of spiders. During exposure therapy, participants will engage in actions opposite of the action tendencies associated with the fear, but unrelated to the specific threats associated with spider phobia. Prior to exposure therapy, participants will receive education about spiders and the development and maintenance of spider phobia.

Outcome Measures

Primary Outcome Measures

  1. Change in Performance on a Behavioral Approach Test in a Generalization Context (Pre-treatment to 2-week Follow-Up) [Change from pre-treatment (same day as treatment) to follow-up (window of 14-21 days after treatment)]

    Change in peak subjective fear (0 - 100 scale), behavioral approach (0 - 13 scale), and physiological reactivity (heart rate and skin conductance) to a live spider not used during treatment (generalization context) from pre-treatment to follow-up

Secondary Outcome Measures

  1. Change in Performance on a Behavioral Approach Test in a Generalization Context (Pre-treatment to Post-treatment) [Change from pre-treatment (same day as treatment) to post-treatment (within 30 minutes of completion of the treatment procedure)]

    Change in peak subjective fear (0 - 100 scale), behavioral approach (0 - 13 scale), and physiological reactivity (heart rate and skin conductance) to a live spider not used during treatment (generalization context) from pre-treatment to post-treatment.

  2. Change in Performance on a Behavioral Approach Test in the Treatment Context (Pre-treatment to 2-week Follow-Up) [Change from pre-treatment (same day as treatment) to follow-up (window of 14-21 days after treatment)]

    Change in peak subjective fear (0 - 100), behavioral approach (0 - 10), and physiological reactivity (heart rate and skin conductance) to a live spider used during treatment (treatment context) from pre-treatment to follow-up

  3. Change in Performance on a Behavioral Approach Test in the Treatment Context (Pre-treatment to Post-treatment) [Change from pre-treatment (same day as treatment) to post-treatment (within 30 minutes of completion of the treatment procedure)]

    Change in peak subjective fear (0 - 100), behavioral approach (0 - 10), and physiological reactivity (heart rate and skin conductance) to a live spider used during treatment (treatment context) from pre-treatment to post-treatment.

  4. Change in Fear of Spiders Questionnaire (Pre-treatment to 2-week Follow-Up) [Change from pre-treatment (same day as treatment) to follow-up (window of 14-21 days after treatment)]

    Change in psychometrically validated questionnaire assessing spider phobia severity from pre-treatment to follow-up.

  5. Change in Armfield and Mattiske Disgust Questionnaire (Pre-treatment to 2-week Follow-Up) [Change from pre-treatment (same day as treatment) to follow-up (window of 14-21 days after treatment)]

    Change in psychometrically validated questionnaire assessing severity of disgust response related to spider phobia from pre-treatment to follow-up.

  6. Change in Spider Belief Questionnaire from pre-treatment to follow-up (Pre-treatment to 2-Week Follow-Up) [Change from pre-treatment (same day as treatment) to follow-up (window of 14-21 days after treatment)]

    Change in psychometrically validated questionnaire assessing cognitions related to spider phobia from pre-treatment to follow-up.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • At Prescreen:

  • Total score of greater than or equal to 70 on the Fear of Spiders - Questionnaire (with higher scores indicating higher fear levels).

  • Indicates ongoing fear of spiders and inability to complete close approach towards spiders on brief questionnaire.

  • At Screening visit: inability to complete close approach toward spiders as determined by the treatment context and generalization context Behavioral Approach Tests

Exclusion Criteria:
  • Currently receiving psychotherapy for spider phobia

Contacts and Locations

Locations

Site City State Country Postal Code
1 Laboratory for the Study of Anxiety Disorders, University of Texas at Austin Austin Texas United States 78712

Sponsors and Collaborators

  • University of Texas at Austin

Investigators

  • Study Director: Michael J Telch, PhD, The University of Texas at Austin

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Michael J. Telch, Professor, University of Texas at Austin
ClinicalTrials.gov Identifier:
NCT02905279
Other Study ID Numbers:
  • 2015-07-0020
First Posted:
Sep 19, 2016
Last Update Posted:
Dec 8, 2020
Last Verified:
Dec 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Keywords provided by Michael J. Telch, Professor, University of Texas at Austin
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 8, 2020